BIOMAT Database Logo BIOMAT Database Logo

On the processing of HIV-2 envelope glycoproteins. 1989

M A Rey, and A G Hovanessian
Unité d'Oncologie Virale (URA CNRS 153), Institut Pasteur, Paris.

UI MeSH Term Description Entries
D011498 Protein Precursors Precursors, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014759 Viral Envelope Proteins Integral membrane proteins that are incorporated into the VIRAL ENVELOPE. They are glycosylated during VIRAL ASSEMBLY. Envelope Proteins, Viral,Viral Envelope Glycoproteins,Viral Envelope Protein,Virus Envelope Protein,Virus Peplomer Proteins,Bovine Leukemia Virus Glycoprotein gp51,Hepatitis Virus (MHV) Glycoprotein E2,LaCrosse Virus Envelope Glycoprotein G1,Simian Sarcoma Virus Glycoprotein 70,Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus),Viral Envelope Glycoprotein gp55 (Friend Virus),Viral Envelope Proteins E1,Viral Envelope Proteins E2,Viral Envelope Proteins gp52,Viral Envelope Proteins gp70,Virus Envelope Proteins,Envelope Glycoproteins, Viral,Envelope Protein, Viral,Envelope Protein, Virus,Envelope Proteins, Virus,Glycoproteins, Viral Envelope,Peplomer Proteins, Virus,Protein, Viral Envelope,Protein, Virus Envelope,Proteins, Viral Envelope,Proteins, Virus Envelope,Proteins, Virus Peplomer
D015488 HIV Antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens. AIDS Antigens,HIV-Associated Antigens,HTLV-III Antigens,HTLV-III-LAV Antigens,LAV Antigens,Lymphadenopathy-Associated Antigens,T-Lymphotropic Virus Type III Antigens, Human,HIV Associated Antigens,HTLV III Antigens,HTLV III LAV Antigens,Lymphadenopathy Associated Antigens,T Lymphotropic Virus Type III Antigens, Human,Antigens, AIDS,Antigens, HIV,Antigens, HIV Associated,Antigens, HIV-Associated,Antigens, HTLV III,Antigens, HTLV-III,Antigens, HTLV-III-LAV,Antigens, LAV,Antigens, Lymphadenopathy Associated,Antigens, Lymphadenopathy-Associated,Associated Antigens, HIV,Associated Antigens, Lymphadenopathy,III Antigens, HTLV
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669

Related Publications

M A Rey, and A G Hovanessian
Processing of the envelope glycoproteins of pestiviruses.
June 1993, Journal of virology,
M A Rey, and A G Hovanessian
Disulfide bonding controls the processing of retroviral envelope glycoproteins.
December 1991, The Journal of biological chemistry,
M A Rey, and A G Hovanessian
Receptor interference mediated by the envelope glycoproteins of various HIV-1 and HIV-2 isolates.
December 1996, Virus research,
M A Rey, and A G Hovanessian
Structure of trimeric HIV-1 envelope glycoproteins.
November 2013, Proceedings of the National Academy of Sciences of the United States of America,
M A Rey, and A G Hovanessian
The Conformational States of the HIV-1 Envelope Glycoproteins.
August 2020, Trends in microbiology,
M A Rey, and A G Hovanessian
Biodiversity and bioseparation of HIV-1 envelope glycoproteins.
January 1999, Critical reviews in oncogenesis,
M A Rey, and A G Hovanessian
Hypothetical assignment of intrachain disulfide bonds for HIV-2 and SIV envelope glycoproteins.
June 1991, AIDS research and human retroviruses,
M A Rey, and A G Hovanessian
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
June 1998, Science (New York, N.Y.),
M A Rey, and A G Hovanessian
Interactions of HIV-1 and HIV-2 envelope glycoproteins with sulphated polysaccharides and mannose-6-phosphate.
February 1994, Glycobiology,
M A Rey, and A G Hovanessian
Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41.
January 2003, Current pharmaceutical design,
Copied contents to your clipboard!